TAK-285 is primarily investigated for its potential application in cancer treatment, particularly as a kinase inhibitor. It targets specific kinases involved in the signaling pathways that promote cancer cell growth and survival. By inhibiting these kinases, TAK-285 aims to halt the proliferation of cancer cells and induce apoptosis, making it a promising candidate for therapeutic use in various malignancies. Research has focused on its efficacy in treating cancers where kinase signaling pathways are dysregulated, such as certain types of breast cancer, lung cancer, and other solid tumors. Clinical studies are ongoing to evaluate its safety, tolerability, and effectiveness in patients, with the goal of developing it as a targeted therapy for cancer.